<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503202</url>
  </required_header>
  <id_info>
    <org_study_id>V920-012</org_study_id>
    <secondary_id>2015-001658-14</secondary_id>
    <secondary_id>V920-012</secondary_id>
    <nct_id>NCT02503202</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)</brief_title>
  <official_title>A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot
      of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study
      was to demonstrate consistency in the immune responses of participants receiving 3 separate
      lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose
      group and a placebo group were studied. A subset of participants representative of all
      treatment groups continued through 24 months postvaccination in the extension study for the
      evaluation of long-term safety. The primary hypothesis states that the geometric mean titer
      of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is
      equivalent across the three consistency lots.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2015</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">May 2, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody</measure>
    <time_frame>Day 28 postvaccination</time_frame>
    <description>Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Serious Adverse Events</measure>
    <time_frame>Up to Month 6 postvaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card</measure>
    <time_frame>Up to Day 5 postvaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated Maximum Temperature</measure>
    <time_frame>Up to Day 42 postvaccination</time_frame>
    <description>Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card</measure>
    <time_frame>From Day 5 to Day 42 postvaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card</measure>
    <time_frame>Up to Day 42 postvaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card</measure>
    <time_frame>Up to Day 42 postvaccination</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1197</enrollment>
  <condition>Prevention of Ebola Infection</condition>
  <arm_group>
    <arm_group_label>V920 Consistency Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 1.0 mL intramuscular injection of V920 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V920 Consistency Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 1.0 mL intramuscular injection of V920 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V920 Consistency Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 1.0 mL intramuscular injection of V920 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V920 High-dose Lot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 1.0 mL intramuscular injection of V920 on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to V920</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a 1.0 mL intramuscular injection of placebo on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V920 Consistency Lot A</intervention_name>
    <description>V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection</description>
    <arm_group_label>V920 Consistency Lot A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V920 Consistency Lot B</intervention_name>
    <description>V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection</description>
    <arm_group_label>V920 Consistency Lot B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V920 Consistency Lot C</intervention_name>
    <description>V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection</description>
    <arm_group_label>V920 Consistency Lot C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V920 High-dose Lot</intervention_name>
    <description>V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection</description>
    <arm_group_label>V920 High-dose Lot</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to V920</intervention_name>
    <description>Sodium chloride 0.9%, sterile solution for intramuscular injection</description>
    <arm_group_label>Placebo to V920</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not of reproductive potential, or of reproductive potential and agrees to avoid
             becoming pregnant or impregnating a partner for 2 months following study vaccination.

        Exclusion Criteria:

          -  Is currently participating in or has participated in an interventional clinical trial
             with an investigational compound or device within 90 days of participation in this
             trial.

          -  Has previously been randomized in another clinical trial and received V920 or any
             other Ebola vaccine.

          -  Has been exposed to Ebola virus at any time prior to study entry.

          -  Is pregnant or breastfeeding or plans to conceive within 2 months following study
             vaccination.

          -  Has direct household exposure to a pregnant or lactating woman at the time of
             participation in this trial.

          -  Has had a fever (≥100.5ºF/38.0ºC) within 48 hours prior to study entry.

          -  Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of
             prednisone or ≥20 mg/day for persons weighing &gt;10 kg) for ≥14 consecutive days and has
             not completed treatment at least 30 days prior to study entry.

          -  Has received systemic corticosteroids exceeding physiologic replacement doses (~5
             mg/day prednisone equivalent) within 14 days prior to study entry.

          -  Has received any live virus vaccine within 30 days prior to study entry or any other
             (nonlive virus) vaccine within 14 days prior to study entry.

          -  Has known or suspected impairment of immunological function (e.g., HIV positive).

          -  Has direct household exposure to a person with known or suspected impairment of
             immunological function (e.g., HIV positive).

          -  Has a clinically significant history of intravenous (IV) drug abuse within 12 months
             prior to study entry.

          -  Has a known allergy/sensitivity or contraindication to investigational product(s) or
             its/their excipients (e.g., albumin).

          -  Has a history of malignancy &lt;=5 years prior to study entry except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer.

          -  Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
             child) who is investigational site or sponsor staff directly involved with this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, Helmond FA; V920-012 Study Team. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. J Infect Dis. 2017 Jun 15;215(12):1789-1798. doi: 10.1093/infdis/jix189.</citation>
    <PMID>28549145</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <results_first_submitted>September 7, 2018</results_first_submitted>
  <results_first_submitted_qc>October 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2018</results_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1261 participants were screened and 1197 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V920 Consistency Lot A</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
        </group>
        <group group_id="P2">
          <title>V920 Consistency Lot B</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
        </group>
        <group group_id="P3">
          <title>V920 Consistency Lot C</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
        </group>
        <group group_id="P4">
          <title>V920 High-dose Lot</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study: Up to Month 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="267"/>
                <participants group_id="P4" count="266"/>
                <participants group_id="P5" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="264"/>
                <participants group_id="P5" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="253"/>
                <participants group_id="P3" count="252"/>
                <participants group_id="P4" count="255"/>
                <participants group_id="P5" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension: Month 6 to 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="137"/>
                <participants group_id="P5" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="119"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>V920 Consistency Lot A</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
        </group>
        <group group_id="B2">
          <title>V920 Consistency Lot B</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
        </group>
        <group group_id="B3">
          <title>V920 Consistency Lot C</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
        </group>
        <group group_id="B4">
          <title>V920 High-dose Lot</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="265"/>
            <count group_id="B3" value="267"/>
            <count group_id="B4" value="266"/>
            <count group_id="B5" value="133"/>
            <count group_id="B6" value="1197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="13.4"/>
                    <measurement group_id="B2" value="41.5" spread="12.4"/>
                    <measurement group_id="B3" value="40.9" spread="13.1"/>
                    <measurement group_id="B4" value="41.7" spread="13.4"/>
                    <measurement group_id="B5" value="41.1" spread="13.7"/>
                    <measurement group_id="B6" value="41.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="138"/>
                    <measurement group_id="B4" value="149"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="637"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody</title>
        <description>Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.</description>
        <time_frame>Day 28 postvaccination</time_frame>
        <population>Participants who were compliant with the protocol, received vaccination, were seronegative at Day 1, and had a serum sample collected within the acceptable day range</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody</title>
          <description>Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.</description>
          <population>Participants who were compliant with the protocol, received vaccination, were seronegative at Day 1, and had a serum sample collected within the acceptable day range</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="226"/>
                <count group_id="O4" value="219"/>
                <count group_id="O5" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1183.9" lower_limit="1038.7" upper_limit="1349.4"/>
                    <measurement group_id="O2" value="1266.0" lower_limit="1108.2" upper_limit="1446.2"/>
                    <measurement group_id="O3" value="1346.0" lower_limit="1176.6" upper_limit="1539.9"/>
                    <measurement group_id="O4" value="1291.9" lower_limit="1126.9" upper_limit="1481.2"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Geometric Mean and CIs are &lt;36.11 EU/mL</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency requires the 95% confidence interval of the GMT ratio of &gt;0.5 and ≤2.0 for the primary analysis and &gt;0.67 and ≤1.5 for the secondary analysis.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Primary analysis: a p-value &lt;0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.</p_value_desc>
            <method>ANOVA</method>
            <param_type>GMT ratio (Lot A / Lot B)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency requires the 95% confidence interval of the GMT ratio of &gt;0.5 and ≤2.0 for the primary analysis and &gt;0.67 and ≤1.5 for the secondary analysis.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Primary analysis: a p-value &lt;0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.</p_value_desc>
            <method>ANOVA</method>
            <param_type>GMT ratio (Lot A / Lot C)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lot consistency requires the 95% confidence interval of the GMT ratio of &gt;0.5 and ≤2.0 for the primary analysis and &gt;0.67 and ≤1.5 for the secondary analysis.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Primary analysis: a p-value &lt;0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.</p_value_desc>
            <method>ANOVA</method>
            <param_type>GMT ratio (Lot B / Lot C)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Serious Adverse Events</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.</description>
        <time_frame>Up to Month 6 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Serious Adverse Events</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="260"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="1.2"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>4.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.989</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.214</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.</description>
        <time_frame>Up to Day 5 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="260"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="14.8"/>
                    <measurement group_id="O4" value="7.3"/>
                    <measurement group_id="O5" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8"/>
                    <measurement group_id="O2" value="73.0"/>
                    <measurement group_id="O3" value="70.3"/>
                    <measurement group_id="O4" value="67.7"/>
                    <measurement group_id="O5" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="18.3"/>
                    <measurement group_id="O4" value="16.2"/>
                    <measurement group_id="O5" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site erythema</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site erythema</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.971</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site erythema</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Injection site erythema</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site pain</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.120</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site pain</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.380</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>94</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site pain</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.499</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Injection site pain</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>54.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>46.2</ci_lower_limit>
            <ci_upper_limit>62.3</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Injection site swelling</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>10.3</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site swelling</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Injection site swelling</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Injection site swelling</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.4</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated Maximum Temperature</title>
        <description>Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).</description>
        <time_frame>Up to Day 42 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Maximum Temperature</title>
          <description>Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="258"/>
                <count group_id="O5" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="22.4"/>
                    <measurement group_id="O4" value="32.2"/>
                    <measurement group_id="O5" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.6</ci_lower_limit>
            <ci_upper_limit>37.5</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.</description>
        <time_frame>From Day 5 to Day 42 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="260"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="5.7"/>
                    <measurement group_id="O3" value="6.5"/>
                    <measurement group_id="O4" value="7.7"/>
                    <measurement group_id="O5" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthritis AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="3.1"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.983</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.716</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Arthralgia</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Arthritis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.677</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arthritis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Arthritis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Arthritis</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.</description>
        <time_frame>Up to Day 42 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="260"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="4.6"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="3.8"/>
                    <measurement group_id="O5" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.353</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.620</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>5.7</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.</description>
        <time_frame>Up to Day 42 postvaccination</time_frame>
        <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
        <group_list>
          <group group_id="O1">
            <title>V920 Consistency Lot A</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
          </group>
          <group group_id="O2">
            <title>V920 Consistency Lot B</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
          </group>
          <group group_id="O3">
            <title>V920 Consistency Lot C</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
          </group>
          <group group_id="O4">
            <title>V920 High-dose Lot</title>
            <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.</description>
          <population>Randomized participants who received vaccination and had follow-up data for the outcome measure</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="263"/>
                <count group_id="O4" value="260"/>
                <count group_id="O5" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.483</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot B</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.746</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot A - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.704</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Risk difference is Lot B - Lot C</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Risk difference is High-dose Lot - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Month 24</time_frame>
      <desc>The at-risk population was randomized participants who received vaccination and had follow-up safety data available.</desc>
      <group_list>
        <group group_id="E1">
          <title>V920 Consistency Lot A</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1</description>
        </group>
        <group group_id="E2">
          <title>V920 Consistency Lot B</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1</description>
        </group>
        <group group_id="E3">
          <title>V920 Consistency Lot C</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1</description>
        </group>
        <group group_id="E4">
          <title>V920 High-dose Lot</title>
          <description>Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants received a 1.0-mL intramuscular injection of placebo on Day 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="260"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Conductive deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="263"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="263"/>
                <counts group_id="E4" subjects_affected="208" subjects_at_risk="260"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="265"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="265"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="263"/>
                <counts group_id="E4" events="27" subjects_affected="27" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="265"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="263"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="263"/>
                <counts group_id="E4" events="21" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="265"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="263"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="265"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="263"/>
                <counts group_id="E3" events="42" subjects_affected="39" subjects_at_risk="263"/>
                <counts group_id="E4" events="23" subjects_affected="19" subjects_at_risk="260"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="198" subjects_affected="179" subjects_at_risk="265"/>
                <counts group_id="E2" events="215" subjects_affected="192" subjects_at_risk="263"/>
                <counts group_id="E3" events="212" subjects_affected="185" subjects_at_risk="263"/>
                <counts group_id="E4" events="192" subjects_affected="176" subjects_at_risk="260"/>
                <counts group_id="E5" events="19" subjects_affected="18" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="51" subjects_affected="47" subjects_at_risk="265"/>
                <counts group_id="E2" events="40" subjects_affected="36" subjects_at_risk="263"/>
                <counts group_id="E3" events="52" subjects_affected="49" subjects_at_risk="263"/>
                <counts group_id="E4" events="42" subjects_affected="42" subjects_at_risk="260"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="265"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="263"/>
                <counts group_id="E3" events="30" subjects_affected="29" subjects_at_risk="263"/>
                <counts group_id="E4" events="33" subjects_affected="32" subjects_at_risk="260"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="58" subjects_at_risk="265"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="263"/>
                <counts group_id="E3" events="70" subjects_affected="63" subjects_at_risk="263"/>
                <counts group_id="E4" events="83" subjects_affected="76" subjects_at_risk="260"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="72" subjects_affected="47" subjects_at_risk="265"/>
                <counts group_id="E2" events="74" subjects_affected="41" subjects_at_risk="263"/>
                <counts group_id="E3" events="75" subjects_affected="50" subjects_at_risk="263"/>
                <counts group_id="E4" events="79" subjects_affected="53" subjects_at_risk="260"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="265"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="263"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="263"/>
                <counts group_id="E4" events="23" subjects_affected="23" subjects_at_risk="260"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="72" subjects_affected="61" subjects_at_risk="265"/>
                <counts group_id="E2" events="56" subjects_affected="51" subjects_at_risk="263"/>
                <counts group_id="E3" events="68" subjects_affected="55" subjects_at_risk="263"/>
                <counts group_id="E4" events="83" subjects_affected="67" subjects_at_risk="260"/>
                <counts group_id="E5" events="18" subjects_affected="15" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

